



MISSION:

TendoNova increases patient access to clinically proven treatments by providing clinicians with affordable specialized tools that offer objective feedback for minimally-invasive orthopedic procedures; we bring surgical level care to the office.

PROBLEM:

Tendinopathy, an injury that is stuck in a static state of healing, can occur in any tendon (tennis elbow, jumpers knee, plantar fasciitis). Conservative treatments such as physical therapy aim to restart the healing process through controlled re-injury, however 40-80% of patients don't have reduction in symptoms.

In the US today, 14 million patients are caught in this gap between conservative treatment and expensive and/or ineffective procedural options such as injections of platelet-rich plasma, proliferation therapy, or percutaneous needle tenotomy (PNT).

While these treatments offer a chance at reduction in symptoms, success rates are highly variable due to a long learning curve and variability in clinician skill. Alternative technologies with higher success rates, such as tools to cut and remove chronically damaged tissue, are hindered by high costs relative to reimbursement - limiting access and adoption.

Clinicians need a financially-efficient, clinically-effective method that can be performed by both novice and expert users.

A NOVEL SYSTEM FOR TREATING TENDON PAIN:

The Ocelot™ system is a novel comprehensive product for performing percutaneous tenotomy, consisting of a hand-held reusable driver, a single-use disposable component, and real-time feedback to the physician on the effect their intervention has on tissue. Additionally, through collection of data, long term clinical effectiveness can be continuously improved through pairing outcomes with objective measurements.

The Ocelot system has been designed to be a cost-effective tool for in-office treatment of chronic tendinopathy, avoiding the need for hospital-based procedures. The result: a system that improves patient experience, reduces cost per procedure, and improves outcomes through standardizing the way clinicians measure their clinical effect. Due to the systems' ease of use, positive patient outcomes, and lower cost than alternative technologies Ocelot becomes an attractive addition to office-based practices.

OPPORTUNITY:

TendoNova's goal is to address the emerging clinical trend of minimally-invasive procedures through simple economical tools that can be deployed in a physician's office.

The total chronic tendinopathy market is \$4.5B with an initial, addressable target market (\$1.2B) comprised of patients who have failed conservative treatment for chronic tendon pain. While this is the largest immediate addressable market for the Ocelot system, it is not the only one. Variations on the system can be developed to address multiple orthopedic procedures currently performed in surgical suites. In addition to being simple and affordable, the Ocelot system captures a broad set of clinical data to assess interventions related to clinical outcomes.

COMPANY

Founded : 2017
Delaware C Corp
Registered and operating in GA and NH - USA

MANAGEMENT

Roy Wallen, CEO - 35+ Years in Med Device
Lou Malice, Chairman - 30+ Years in Med Device

FOUNDERS

Jonathan Shaw - Clinical & Marketing
Luka Grujic- Strategic Product Management
Shawna Khouri - Business & Strategy
Brett Rogers - R&D and Operations

MEDICAL ADVISORY BOARD

Kenneth Mautner, MD - 15+ years in clinical space
Gerald Malanga, MD - 30+ years in clinical space
Rahul Desai MD - Interventional Radiology

FUNDING TO DATE - \$2 Million Raise

\$176k - Grants and Convertible Debt
\$254k - Committed

REGULATORY PATHWAY

510(k)

Intellectual Property - 2 Utility patents pending

Exclusive worldwide license from Emory
Internally developed patent

